Full text is available at the source.
Abstract
GLP1-RAs are approved for use in patients aged ≥10 years for type 2 diabetes and ≥12 years for obesity.
- The study focused on the impact of GLP1-RAs on how long gastric contents remain in fasting adolescents.
- Retention of gastric contents may be influenced by the administration of GLP1-RAs.
- Findings could provide insights into the gastrointestinal effects of GLP1-RAs in younger populations.
Simplified
GLP-1 Therapies